Organon & Co. (NYSE:OGN) Hits New 12-Month High – Here’s Why

Organon & Co. (NYSE:OGN)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $13.48 and last traded at $13.4850, with a volume of 2868323 shares. The stock had previously closed at $13.38.

Analysts Set New Price Targets

OGN has been the topic of several research reports. Zacks Research upgraded shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their target price for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Barclays upped their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 24th. BNP Paribas Exane reiterated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Performance

The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 14.49, a P/E/G ratio of 1.24 and a beta of 1.55. The company’s fifty day simple moving average is $11.32 and its two-hundred day simple moving average is $8.81. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 earnings per share. On average, analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be paid a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s payout ratio is 8.60%.

Insider Buying and Selling

In related news, SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was purchased at an average cost of $13.35 per share, with a total value of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This trade represents a 100.17% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.62% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers grew its holdings in Organon & Co. by 1.7% during the first quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock worth $288,000 after buying an additional 788 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Organon & Co. by 0.6% during the 4th quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after acquiring an additional 1,570 shares in the last quarter. Integrated Wealth Concepts LLC boosted its holdings in Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock worth $626,000 after acquiring an additional 1,594 shares during the last quarter. Rothschild Investment LLC grew its stake in shares of Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after acquiring an additional 1,646 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its stake in shares of Organon & Co. by 8.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock worth $228,000 after acquiring an additional 1,847 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.